Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 14, 2026
Foghorn Therapeutics Inc. (FHTX)
A forensic read on Foghorn Therapeutics Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Distress
Financial health
-8.6
Distress distance
Clean
Earnings quality
3
Forensic signals
-6.1
P / E (ttm)
$385M
Market cap
0.00%
Dividend yield
36.8%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Foghorn Therapeutics Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads -8.6, placing it in the Distress zone. 3 forensic signals were flagged in its latest SEC filings, led by share-count dilution.
What the filings flag
+14.8%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +51% over the last 3 years to FY2025 (+14.8%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~14.8% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~34%.
-$304.6M
FY2023–FY2025
Cash burn vs. reported loss.Over FY2023–FY2025, the company reported a cumulative net loss of $259.3M against operating cash flow of -$304.6M. Cash burn ran heavier than the reported loss — something outside net income (working capital, a cash item not in the P&L) is consuming cash faster than the loss alone implies.
34% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 34% of revenue in FY2025 — about $0.17 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 15.5% a year, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
Key fundamentals
Latest Revenue$30.9M
Revenue Growth YoY+36.8%
Revenue CAGR (3yr)+17.1%
Net Margin-240.3%
Free Cash Flow-$86.1M
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Foghorn Therapeutics Inc.'s actual 10-K/10-Q/8-K filings?